Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{48f33ba69f72495ba691509702f2189b,
title = "Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?",
abstract = "The outcome of patients who have early unfavorable or intermediate-stage Hodgkin's lymphoma has greatly improved. The increasing efficacy of chemotherapy and late toxic effects of wide-field radiotherapy justify the careful testing of the new involved-node radiotherapy principle in the combined-modality approach. For the purpose of tailoring treatment to the individual patient we need more accurate measures, preferably predictive factors that may tell us how the individual patient should be treated. The result of an early positron emission tomography scan with fluorodeoxyglucose may well become the major new treatment-related guidance for an individually tailored treatment approach.",
author = "Lena Specht and John Raemaekers",
year = "2007",
month = "10",
day = "1",
doi = "10.1016/j.hoc.2007.07.002",
language = "English",
volume = "21",
pages = "881--96",
journal = "Hematology / Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B./Saunders Co",
number = "5",

}

RIS

TY - JOUR

T1 - Do we need an early unfavorable (intermediate) stage of Hodgkin's lymphoma?

AU - Specht, Lena

AU - Raemaekers, John

PY - 2007/10/1

Y1 - 2007/10/1

N2 - The outcome of patients who have early unfavorable or intermediate-stage Hodgkin's lymphoma has greatly improved. The increasing efficacy of chemotherapy and late toxic effects of wide-field radiotherapy justify the careful testing of the new involved-node radiotherapy principle in the combined-modality approach. For the purpose of tailoring treatment to the individual patient we need more accurate measures, preferably predictive factors that may tell us how the individual patient should be treated. The result of an early positron emission tomography scan with fluorodeoxyglucose may well become the major new treatment-related guidance for an individually tailored treatment approach.

AB - The outcome of patients who have early unfavorable or intermediate-stage Hodgkin's lymphoma has greatly improved. The increasing efficacy of chemotherapy and late toxic effects of wide-field radiotherapy justify the careful testing of the new involved-node radiotherapy principle in the combined-modality approach. For the purpose of tailoring treatment to the individual patient we need more accurate measures, preferably predictive factors that may tell us how the individual patient should be treated. The result of an early positron emission tomography scan with fluorodeoxyglucose may well become the major new treatment-related guidance for an individually tailored treatment approach.

U2 - 10.1016/j.hoc.2007.07.002

DO - 10.1016/j.hoc.2007.07.002

M3 - Journal article

VL - 21

SP - 881

EP - 896

JO - Hematology / Oncology Clinics of North America

JF - Hematology / Oncology Clinics of North America

SN - 0889-8588

IS - 5

ER -

ID: 32265562